- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | Prime Medicine, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.12.25 | Prime Medicine, Inc.: Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease | 2 | GlobeNewswire (USA) | ||
| 13.11.25 | Goldman Sachs reiterates Early-Stage Biotech rating on Prime Medicine stock | 5 | Investing.com | ||
| PRIME MEDICINE Aktie jetzt für 0€ handeln | |||||
| 07.11.25 | Prime Medicine GAAP EPS of -$0.32 misses by $0.06, revenue of $1.2M misses by $1.6M | 2 | Seeking Alpha | ||
| 07.11.25 | Prime Medicine, Inc.: Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates | 2.013 | GlobeNewswire (Europe) | -- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as... ► Artikel lesen | |
| 07.11.25 | Prime Medicine, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.11.25 | Prime Medicine, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11.25 | Prime Medicine appoints Matthew Hawryluk as chief business officer | 2 | Investing.com | ||
| 03.11.25 | Prime Medicine, Inc.: Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer | 274 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies... ► Artikel lesen | |
| 30.10.25 | Prime Medicine, Inc.: Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy | 7 | GlobeNewswire (USA) | ||
| 08.09.25 | Prime Medicine, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08.25 | Prime Medicine, Inc.: Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates | 562 | GlobeNewswire (Europe) | -- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions... ► Artikel lesen | |
| 19.05.25 | Prime Medicine, Inc.: Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease | 515 | GlobeNewswire (Europe) | -- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity... ► Artikel lesen | |
| 19.05.25 | Prime Medicine, Inc.: Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition | 435 | GlobeNewswire (Europe) | -- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or... ► Artikel lesen | |
| 18.03.25 | Prime Medicine, Inc.: Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) | 344 | GlobeNewswire (Europe) | -- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- --... ► Artikel lesen | |
| 28.02.25 | Prime Medicine, Inc.: Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates | 1.632 | GlobeNewswire (Europe) | -- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,10 | -0,21 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| QIAGEN | 41,960 | +1,38 % | Qiagen: Analysten sehen Wettbewerbssorgen als übertrieben | Nach Gesprächen mit dem Qiagen-Management auf Analysten-Konferenzen in den USA stufen Analysten die Aktie des Diagnostikspezialisten weiterhin positiv ein. Jefferies beließ es bei einer Kaufempfehlung... ► Artikel lesen | |
| MODERNA | 45,160 | -0,41 % | Moderna's combination flu, COVID shot wins over European drug regulators | ||
| AMGEN | 328,50 | -0,02 % | Is Amgen Stock Outperforming the Dow? | ||
| NOVAVAX | 8,495 | -0,97 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 162,45 | +0,06 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology | SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| ILLUMINA | 113,72 | -0,09 % | Evercore ISI reiterates Illumina stock rating on competitive positioning | ||
| CRISPR THERAPEUTICS | 50,50 | -0,98 % | Crispr Therapeutics gains amid takeover speculation | ||
| VIKING THERAPEUTICS | 28,340 | -1,19 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| MAINZ BIOMED | 0,748 | +2,78 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| INTELLIA THERAPEUTICS | 11,645 | -0,13 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites... ► Artikel lesen | |
| TEMPUS AI | 45,000 | -0,44 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,342 | -0,92 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,420 | -1,18 % | Validierte Exosomen-Chargen, klarer Fahrplan: Wie NurExone Biologic Schritt für Schritt Richtung Klinik voranschreitet | ||
| BIOMARIN PHARMACEUTICAL | 52,88 | +1,23 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen |
Das Unternehmen PRIME MEDICINE INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,250 (+5,71 %) liegt der Kurs bei 4,630 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRIME MEDICINE INC finden Sie auf Wallstreet Online.